CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • February 1st, 2021 • Adagene Inc. • Pharmaceutical preparations • California
THIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of February 1, 2021 (the “Effective Date”), by and between EXELIXIS, INC., a Delaware corporation having an address at 1851 Harbor Bay Parkway, Alameda, CA 94502, USA (“Exelixis”) and ADAGENE INCORPORATED, a Delaware corporation having an address at 315 Montgomery Street, Suite 900, San Francisco, CA 94104 (“Adagene”). Exelixis and Adagene may be referred to herein individually as a “Party” or collectively as the “Parties”.
